Skip to main content

Severe Combined Immunodeficiency Due to RAG1 Deficiency

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Genewity
GenewityNetherlands - Oegstgeest
1 program
1
Gene therapyPhase 1/2Gene Therapy1 trial
Active Trials
NCT04797260Suspended10Est. Dec 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenewityGene therapy

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID

Start: Jul 2021Est. completion: Dec 203110 patients
Phase 1/2Suspended

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.